Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3361237 in Psoriasis
NCT04975295Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing LY3361237 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Jul 2021; status: completed.
02
Drugs
venanprubart
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04975295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975295.